Effect of Ranolazine on A1C and Glucose Levels in Hyperglycemic Patients With Non-ST Elevation Acute Coronary Syndrome
Open accessThe DOI matches its Crossref record; 24 of the 25 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: We determined the relationships between glycemia at randomization, concurrent antidiabetic therapy, and change in A1C and fasting plasma glucose (FPG) in patients with diabetes receiving standard treatment for diabetes and randomized to ranolazine or placebo within the MERLIN-TIMI-36 (MERLIN) study. Ranolazine is a novel first-in-class drug approved for treating angina pectoris. RESEARCH DESIGN AND METHODS: Randomization and 4-month glycemic and antidiabetes drug usage data from MERLIN were analyzed using Spotfire and SAS version 9.1 software. RESULTS: In patients with diabetes and A1C of ≥8–10% at randomization (n = 171), there was an absolute A1C reduction in the ranolazine group of 1.2% (95% CI −1.4 to −1.0), and the placebo-adjusted (n = 182) decrease in A1C by ranolazine was 0.59% (95% CI −0.99 to −0.20, P < 0.001). In patients with FPG of 150–400 mg/dl at randomization, ranolazine (n = 131) compared with placebo (n = 147) reduced FPG by 25.7 mg/dl (95% CI −43.3 to −8.1, P = 0.001). When changes in either A1C or FPG were correlated to A1C or FPG at randomization, the slopes were significantly steeper for ranolazine than placebo (A1C, P = 0.046; FPG, P < 0.001), indicating that lowering of A1C and FPG by ranolazine is related to hyperglycemia at randomization. Ranolazine, compared with placebo, was not associated with serious hypoglycemic events, associated with significant changes in concurrent antidiabetic therapy, or dependent on a history of angina. CONCLUSIONS: Ranolazine, when added to concurrent antidiabetes treatment, lowers FPG and A1C in patients with cardiovascular disease and poorly controlled diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Both the antianginal effect259 and the glucose-lowering effect260–262 of ranolazine appear to be enhanced in patients with poorly controlled T2DM.”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [262]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus
Selvin, E., Marinopoulos, S., Berkenblit, G., Rami, T., Brancati, F. L., Powe, N. R., & Golden, S. H. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-6-200409210-00007 · Cited by 1,657
Authors/Task Force Members, Ryden, L., Standl, E., Bartnik, M., Van den Berghe, G., Betteridge, J., de Boer, M.-J., Cosentino, F., Jonsson, B., Laakso, M., et al. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl260 · Cited by 1,647
Norhammar, A., Tenerz, Å., Nilsson, G., Hamsten, A., Efendíc, S., Rydén, L., & Malmberg, K. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09089-x · Cited by 1,112
Chaitman, B. R., Skettino, S. L., Parker, J. O., Hanley, P., Meluzin, J., Kuch, J., Pepine, C. J., Wang, W., Nelson, J. J., Hebert, D. A., et al. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2003.11.045 · Cited by 567
Morrow, D. A. (2007) · JAMA · doi:10.1001/jama.297.16.1775 · Cited by 507
Self-citationBelardinelli, L., Shryock, J. C., & Fraser, H. (2006) · Heart · doi:10.1136/hrt.2005.078790 · Cited by 386
Self-citationAntianginal Efficacy of Ranolazine When Added to Treatment With Amlodipine
Stone, P. H., Gratsiansky, N. A., Blokhin, A., Huang, I.-Z., & Meng, L. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.05.044 · Cited by 355
Lower Baseline Glycemia Reduces Apparent Oral Agent Glucose-Lowering Efficacy
Bloomgarden, Z. T., Dodis, R., Viscoli, C. M., Holmboe, E. S., & Inzucchi, S. E. (2006) · Diabetes Care · doi:10.2337/dc06-1120 · Cited by 219
Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes
Timmis, A. D., Chaitman, B. R., & Crager, M. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehi495 · Cited by 193
Mozaffarian, D., Marfisi, R., Levantesi, G., Silletta, M. G., Tavazzi, L., Tognoni, G., Valagussa, F., & Marchioli, R. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61343-9 · Cited by 179
Pathophysiology and pharmacology of the cardiac “late sodium current”
Zaza, A., Belardinelli, L., & Shryock, J. C. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.06.001 · Cited by 177
Self-citationMorrow, D. A., Scirica, B. M., Chaitman, B. R., McGuire, D. K., Murphy, S. A., Karwatowska-Prokopczuk, E., McCabe, C. H., & Braunwald, E. (2009) · Circulation · doi:10.1161/circulationaha.107.763912 · Cited by 170
Self-citationSelvin, E., Coresh, J., Golden, S. H., Boland, L. L., Brancati, F. L., & Steffes, M. W. (2005) · Diabetes Care · doi:10.2337/diacare.28.8.1965 · Cited by 161
Late sodium current inhibition as a new cardioprotective approach
Hale, S. L., Shryock, J. C., Belardinelli, L., Sweeney, M. L., & Kloner, R. A. (2008) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2008.03.019 · Cited by 152
Self-citationHashimoto, K., Ikewaki, K., Yagi, H., Nagasawa, H., Imamoto, S., Shibata, T., & Mochizuki, S. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1182 · Cited by 79
Raj, S. R., Rose, S., Ritchie, D., & Sheldon, R. S. (2006) · American Heart Journal · doi:10.1016/j.ahj.2006.03.013 · Cited by 79
Morrow, D. A., Scirica, B. M., Karwatowska‐Prokopczuk, E., Skene, A. M., McCabe, C. H., & Braunwald, E. (2006) · American Heart Journal · doi:10.1016/j.ahj.2006.01.004 · Cited by 74
Self-citationNon-Insulin Antidiabetic Therapy in Cardiac Patients: Current Problems and Future Prospects
Fisman, E. Z., Motro, M., & Tenenbaum, A. (2008) · Advances in cardiology · doi:10.1159/000115193 · Cited by 65
Ranolazine in patients with angina and coronary artery disease
Scirica, B. M., & Morrow, D. A. (2007) · Current Cardiology Reports · doi:10.1007/bf02938375 · Cited by 15
Self-citation
Research works printed but not linked: 1
- Dhalla, 2008, Ranolazine increases glucose stimulated insulin secretion in rats, J Am Coll Cardiol, 51, A321
Cited by
Arnold, S. V., Bhatt, D. L., Barsness, G. W., Beatty, A. L., Deedwania, P. C., Inzucchi, S. E., Kosiborod, M., Leiter, L. A., Lipska, K. J., Newman, J. D., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000766 · Cited by 304
Evaluation of Ranolazine in Patients With Type 2 Diabetes Mellitus and Chronic Stable Angina
Kosiborod, M., Arnold, S. V., Spertus, J. A., McGuire, D. K., Li, Y., Yue, P., Ben-Yehuda, O., Katz, A., Jones, P. G., Olmsted, A., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.02.011 · Cited by 205
Self-citationRole of ranolazine in angina, heart failure, arrhythmias, and diabetes
Sossalla, S. T., & Maier, L. S. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.11.003 · Cited by 106
BUNCH, T. J., MAHAPATRA, S., MURDOCK, D., MOLDEN, J., WEISS, J. P., MAY, H. T., BAIR, T. L., MADER, K. M., CRANDALL, B. G., DAY, J. D., et al. (2011) · Pacing and Clinical Electrophysiology · doi:10.1111/j.1540-8159.2011.03208.x · Cited by 101
Concomitant Diabetes Mellitus and Heart Failure
Dei, A., Fonarow, G. C., Gheorghiade, M., & Butler, J. (2014) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2014.09.002 · Cited by 94
Metadata
- Authors
- Chisholm, J. W., Goldfine, A. B., Dhalla, A. K., Braunwald, E., Morrow, D. A., Karwatowska-Prokopczuk, E., & Belardinelli, L.
- Affiliations
- Gilead Sciences (United States) (US)
- Joslin Diabetes Center (US)
- TIMI Study Group, Brigham and Women's Hospital and Department of Medicine, Boston, Massachusetts;
- Brigham and Women's Hospital (US)
- Division of Cardiovascular Therapeutics, Gilead Sciences, Palo Alto, California;
- Corresponding author
- Chisholm, Jeffrey W.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2010-03-31
- Volume
- 33
- Issue
- 6
- Pages
- 1163-1168
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC2875416
- OpenAlex
- W2130710856
- Cited by
- 78
- References
- 25
- Citations by year
- 2026: 1 · 2025: 4 · 2022: 2 · 2021: 3 · 2020: 6 · 2019: 3 · 2018: 6 · 2017: 2 · 2016: 9 · 2015: 7 · 2014: 9 · 2013: 13 · 2012: 4
- FWCI
- 6.29
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Gilead Sciences
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Keywords
- ranolazine, glycemic control, HbA1c, fasting blood glucose, hyperglycemia, non-ST-elevation acute coronary syndrome, diabetes mellitus, antidiabetic therapy, hypoglycemia, angina pectoris, cardiovascular disease
- MeSH terms
- Ranolazine, Acetanilides, Aged, Blood Glucose, Enzyme Inhibitors, Female, Glycated Hemoglobin, Humans, Hyperglycemia, Hypoglycemic Agents, Male, Middle Aged, Piperazines, Placebo Effect, Acute Coronary Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.